X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (133078) 133078
Newsletter (4729) 4729
Newspaper Article (1473) 1473
Book Chapter (393) 393
Dissertation (305) 305
Magazine Article (215) 215
Conference Proceeding (133) 133
Government Document (89) 89
Book / eBook (72) 72
Publication (51) 51
Reference (16) 16
Web Resource (14) 14
Streaming Video (11) 11
Paper (8) 8
Transcript (5) 5
Book Review (3) 3
Journal / eJournal (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pyridine (45348) 45348
humans (27004) 27004
animals (25917) 25917
pyridines - pharmacology (24601) 24601
male (18526) 18526
pyridines (15809) 15809
pyridine derivatives (13790) 13790
fused pyridine derivatives (13535) 13535
female (11719) 11719
rats (11235) 11235
analysis (10515) 10515
chemistry, organic (9783) 9783
pyridines - chemistry (9608) 9608
pyridines - therapeutic use (9352) 9352
chemistry, multidisciplinary (9071) 9071
alkaloids (8278) 8278
mice (7922) 7922
chemistry (7770) 7770
pharmacology & pharmacy (7651) 7651
chemistry, physical (7260) 7260
ring closure reactions (6960) 6960
ligands (6919) 6919
research (6863) 6863
chemistry, inorganic & nuclear (6447) 6447
derivatives (6330) 6330
catalysis (6136) 6136
middle aged (6039) 6039
biochemistry & molecular biology (5860) 5860
adult (5648) 5648
imidazoles - pharmacology (5635) 5635
chemical properties (5246) 5246
pyridines - administration & dosage (5230) 5230
dose-response relationship, drug (5141) 5141
molecular structure (5020) 5020
pyridin (4398) 4398
aged (4318) 4318
complexes (4139) 4139
chemistry, medicinal (4028) 4028
enzyme inhibitors - pharmacology (4016) 4016
pyridines - chemical synthesis (4003) 4003
pyridines - adverse effects (3967) 3967
oncology (3946) 3946
kinetics (3931) 3931
structure (3771) 3771
structure-activity relationship (3518) 3518
cancer (3395) 3395
neurosciences (3351) 3351
rats, sprague-dawley (3289) 3289
time factors (3257) 3257
pyridines - metabolism (3219) 3219
cells, cultured (3164) 3164
spectroscopy (3126) 3126
cell line, tumor (3097) 3097
synthesis (3075) 3075
activation (3001) 3001
models, molecular (2980) 2980
in vitro techniques (2877) 2877
expression (2824) 2824
polymers (2725) 2725
catalysts (2692) 2692
adsorption (2668) 2668
amines (2538) 2538
cell biology (2538) 2538
pyridines - pharmacokinetics (2532) 2532
heterocyclic compounds (2514) 2514
phosphorylation (2443) 2443
organic chemistry (2429) 2429
organic compounds (2352) 2352
apoptosis (2341) 2341
chemistry, analytical (2327) 2327
oxidation (2305) 2305
solvents (2290) 2290
treatment outcome (2279) 2279
crystallography (2254) 2254
crystals (2227) 2227
crystal structure (2205) 2205
copper (2192) 2192
fluorescence (2187) 2187
cell line (2153) 2153
proteins (2143) 2143
antineoplastic agents - pharmacology (2131) 2131
engineering, chemical (2126) 2126
crystal-structure (2125) 2125
palladium (2115) 2115
rats, wistar (2078) 2078
inhibition (2059) 2059
materials science, multidisciplinary (2037) 2037
hydrogen (2025) 2025
ligand (2018) 2018
inhibitors (2001) 2001
spectra (1984) 1984
usage (1979) 1979
niacinamide - analogs & derivatives (1958) 1958
cycloaddition reactions (1952) 1952
oxidation-reduction (1933) 1933
disease models, animal (1900) 1900
chemistry, applied (1882) 1882
polymer science (1873) 1873
binding (1864) 1864
antineoplastic agents - therapeutic use (1861) 1861
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (32) 32
Online Resources - Online (15) 15
University Archives - Archives (9) 9
Gerstein Science - Theses (6) 6
UofT at Mississauga - Stacks (5) 5
Chemistry (A D Allen) - Stacks (4) 4
Earth Sciences (Noranda) - Stacks (2) 2
Chemistry (A D Allen) - In transit (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Robarts - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (135791) 135791
Japanese (1846) 1846
German (1789) 1789
Chinese (842) 842
French (734) 734
Russian (595) 595
Italian (495) 495
Spanish (212) 212
Polish (153) 153
Portuguese (117) 117
Czech (58) 58
Dutch (54) 54
Hungarian (45) 45
Ukrainian (36) 36
Danish (29) 29
Korean (27) 27
Swedish (21) 21
Norwegian (18) 18
Bulgarian (11) 11
Croatian (10) 10
Serbian (7) 7
Romanian (6) 6
Arabic (5) 5
Slovak (5) 5
Turkish (4) 4
Finnish (3) 3
Hebrew (3) 3
Catalan (1) 1
Lithuanian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chemistry – A European Journal, ISSN 0947-6539, 10/2010, Volume 16, Issue 40, pp. 12052 - 12062
Journal Article
Advanced synthesis & catalysis, ISSN 1615-4150, 2017, Volume 359, Issue 15, pp. 2676 - 2681
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2013, Volume 49, Issue 16, pp. 3412 - 3419
Abstract Purpose We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following... 
Hematology, Oncology and Palliative Medicine | Second line | Regorafenib | Hepatocellular carcinoma | Tolerability | Safety | Receptor kinase inhibition | Safety Second line | MANAGEMENT | EFFICACY | ONCOLOGY | SUNITINIB | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - mortality | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Liver Neoplasms - enzymology | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Treatment Outcome | Carcinoma, Hepatocellular - enzymology | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Neoplasm Staging | Care and treatment | Safety and security measures | Hepatoma | Index Medicus
Journal Article
Angewandte Chemie (International ed.), ISSN 1433-7851, 2013, Volume 52, Issue 16, pp. 4418 - 4421
Journal Article
Advanced synthesis & catalysis, ISSN 1615-4150, 2014, Volume 356, Issue 4, pp. 687 - 691
A mild, catalytic, atom economical synthesis of imidazo[1,2‐a]pyridines has been developed: catalytic dichloro(2‐pyridinecarboxylato)gold [PicAuCl2] in the... 
gold | atom economy | pyridine N‐oxides | imidazo[1,2‐a]pyridines | redox reaction | alkynes | pyridine N-oxides | imidazo[1,2-a]pyridines | Alkaloids | Oxides | Usage | Pyridine | Economics | Pyridines | Synthesis | Catalysts | Strategy | Catalysis | Alkynes
Journal Article
Advanced Synthesis & Catalysis, ISSN 1615-4150, 07/2018, Volume 360, Issue 14, pp. 2638 - 2643
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Chemistry : a European journal, ISSN 0947-6539, 09/2020, Volume 26, Issue 49, p. 11187
Discrete molecular species that can perform certain functions in response to multiple external stimuli constitute a special class of multifunctional molecular... 
Pyridine
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2017, Volume 356, Issue 6342, pp. 1084 - 1087
A recent phase 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the death of one volunteer and produced mild-to-severe... 
MOLECULAR CHARACTERIZATION | ENZYME | PAIN | ACID AMIDE HYDROLASE-1 | CLINICAL-TRIAL | MULTIDISCIPLINARY SCIENCES | ANANDAMIDE | RECEPTOR | BLOCKADE | ESTERASE | PF-04457845 | Anti-Anxiety Agents - metabolism | Analgesics - pharmacology | Pyridines - chemistry | Humans | Analgesics - metabolism | Pyridazines - pharmacology | Protein Interaction Maps | Pyridines - adverse effects | Cyclic N-Oxides - adverse effects | Cyclic N-Oxides - pharmacology | Urea - analogs & derivatives | Cyclic N-Oxides - metabolism | Anti-Anxiety Agents - adverse effects | Anti-Anxiety Agents - chemistry | Neurons - metabolism | Neurons - drug effects | Pyridazines - therapeutic use | Analgesics - adverse effects | Anti-Anxiety Agents - pharmacology | Amidohydrolases - antagonists & inhibitors | Cross Reactions | Cyclic N-Oxides - chemistry | Urea - therapeutic use | Pyridines - metabolism | Analgesics - chemistry | Cell Line, Tumor | Pyridines - pharmacology | Clinical Trials, Phase I as Topic | Urea - pharmacology | Amino acid sequence | Methods | Fatty-acid amide hydrolase | Brain | Profiling | Hydrolase | Neurons | Therapeutic applications | Nervous system | Tissue analysis | Metabolism | Lipase | Tissues | Fatty acids | Proteins | Neurotoxicity | Cannabinoids | Pain | Inhibitors | Brain damage | Anxiety | Lipid metabolism | Brain injury | Index Medicus | Drugs | Networks | Proteomics | Amides
Journal Article